Variable | Methylation status | P-value | |
---|---|---|---|
 | Absent | Present |  |
Age (mean ± SD) | 57.5 ± 8.4 | 60.0 ± 8.2 | 0.3037 |
Sex | Â | Â | 0.4900 |
   Male | 26 (56.5%) | 20 (43.5%) |  |
   Female | 1 (25.0%) | 3 (75.0%) |  |
Pathological stage | Â | Â | 0.8766 |
   I | 9 (50.0%) | 9 (50.0%) |  |
   II | 6 (50.0%) | 6 (50.0%) |  |
   III | 10 (62.5%) | 6 (37.5%) |  |
   IV | 2 (50.0%) | 2 (50.0%) |  |
Differentiation | Â | Â | 0.3890 |
   Well | 1 (50.0%) | 1 (50.0%) |  |
   Moderate | 15 (48.4%) | 16 (51.6%) |  |
   Poor | 8 (57.1%) | 6 (42.9%) |  |
   Unknown | 3 (100.0%) | 0 (0.0%) |  |
Tumor size (cm) (mean ± SD) | 4.19 ± 2.34 | 4.62 ± 2.62 | 0.6543 |
Tumor status | Â | Â | 0.2946 |
   T1 | 11 (61.1%) | 7 (38.9%) |  |
   T2 | 12 (46.2%) | 14 (53.8%) |  |
   T3 | 2 (66.7%) | 1 (33.3%) |  |
   T4 | 1 (100.0%) | 0 (0.0%) |  |
   Tx | 2 (100.0%) | 0 (0.0%) |  |
Metastatic status | Â | Â | 0.6871 |
   Primary tumor | 22 (61.1%) | 14 (38.9%) |  |
   Lymph node metastasis | 4 (40.0%) | 6 (60.0%) |  |
   Distant metastasis | 2 (50.0%) | 2 (50.0%) |  |
Histology | Â | Â | 0.6614 |
   Adenocarcinoma | 14 (58.3%) | 10 (41.7%) |  |
   Squamous cell carcinoma | 12 (52.2%) | 11 (47.8%) |  |